Table 4.
Comparison clinicopathological characteristics of high-grade serous ovarian carcinomas (HGSOC) patients with and without serum tumor-specific TP53 mutation at diagnosis.
| HGSOC Patients Serum cfDNA at Diagnosis: | |||
|---|---|---|---|
| Without Tumor-Cpecific TP53 Mutation | With Tumor-Specific TP53 Mutation | p-Value | |
| Number of patients | 8 | 9 | |
| Average TP53 mutation allele frequency (MAF in %): | |||
| in tumor tissue | 58% | 62% | 0.819 |
| in cfDNA | 0% | 7% | 0.115 |
| NGS workflow (N): | |||
| I | 4 | 4 | 0.819 |
| II | 4 | 5 | |
|
Age at diagnosis (average):
|
57 | 55 | 0.703 |
| FIGO Stage (N): | |||
| IC | 1 | 0 | 0.024 |
| IIIC | 6 | 2 | |
| IV | 1 | 7 | |
| Debulking surgery (N): | |||
| PDS | 4 | 3 | 0.614 |
| IDS | 4 | 5 | |
| Residual Disease (N): | |||
| 0–1 cm (optimal debulking) | 6 | 5 | 0.402 |
| 1 cm or more (non-optimal debulking) | 2 | 5 | |
| Progression-Free Survival (PFS): | |||
| 0–6 months (n) | 1 | 3 | 0.312 |
| >6 months (n) | 7 | 6 | |
| average cfDNA yield (ng/mL serum): | |||
| at diagnosis | 129 | 95 | 0.363 |
| after chemotherapy | 31 | 45 | 0.106 |
| at progression | 117 | 45 | 0.268 |
| TP53 mutation at progression measured by dPCR (N): | |||
| Yes | 1 | 4 | 0.079 |
| No | 1 | 0 | |
| Other gene mutations detected in cfDNA at diagnosis: | |||
| PIK3CA p.H1047R | 1.30% | ||
| ESR1 p.R394S | 0.30% | ||
| TP53 p.T253I * | 0.10% | ||
PDS = primary Debulking surgery, IDS = interval Debulking surgery, NGS = next generation sequencing, dPCR = digital PCR, N = number of patients, * = TP53 p.T253I was identified in serum but not in tumor tissue.